Direkt zum Inhalt
Merck

1224981

USP

Donepezil -hydrochlorid

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

(±)-2-[(1-Benzyl-4-piperidyl)-methyl]-5,6-dimethoxy-1-indanon -hydrochlorid, 2,3-Dihydro-5,6-dimethoxy-2-{[1-(phenylmethyl)-4-piperidinyl]-methyl}-1H-inden-1-on

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

1224981-200MG

€ 1.820,00

€ 1.820,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen

Über diesen Artikel

Empirische Formel (Hill-System):
C24H29NO3 · HCl
CAS-Nummer:
Molekulargewicht:
415.95
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

grade

pharmaceutical primary standard

API family

donepezil

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl.N2(CCC(CC2)CC3Cc4c(cc(c(c4)OC)OC)C3=O)Cc1ccccc1

InChI

1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H

InChI key

XWAIAVWHZJNZQQ-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
Y0002160PHR1584D6821
grade

pharmaceutical primary standard

grade

-

grade

certified reference material, pharmaceutical secondary standard

grade

-

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

-

manufacturer/tradename

-

format

neat

format

-

format

neat

format

-

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical (small molecule)

application(s)

-

API family

donepezil

API family

donepezil

API family

donepezil

API family

-

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2

Lagerklasse

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Manabu Ikeda et al.
Dementia and geriatric cognitive disorders, 36(3-4), 229-241 (2013-08-21)
To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB). This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized
Yusuke Yatabe et al.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 13(2), 88-93 (2013-08-06)
With the recent approval of several new drugs, pharmacological management of Alzheimer's disease has become more complicated in Japan. The efficacy and safety of increasing the dose of donepezil to 10 mg daily were assessed in an open-label study of patients
Marwan Sabbagh et al.
BMC geriatrics, 13, 56-56 (2013-06-08)
Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated
Masaru Ishibashi et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(34), 12538-12543 (2014-08-13)
Nicotinic and muscarinic ACh receptor agonists and acetylcholinesterase inhibitors (AChEIs) can enhance cognitive function. However, it is unknown whether a common signaling pathway is involved in the effect. Here, we show that in vivo administration of nicotine, AChEIs, and an
Jong-Il Kim et al.
International journal of pharmaceutics, 455(1-2), 31-39 (2013-08-13)
Although the taste-masking of bitter drug using ion exchange resin has been recognized, in vitro testing using an electronic tongue (e-Tongue) and in vivo bitterness test by human panel test was not fully understood. In case of orally disintegrating tablet

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung